Iqvia Holdings Stock News

IQVIA Holdings Inc. (IQV) CEO Ari Bousbib on Q4 2021 Results - Earnings Call Transcript

IQVIA (IQV) delivered earnings and revenue surprises of 4.94% and 1.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • FirstService (NASDAQ: FSV ) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. • Fidelity National Info (NYSE: FIS ) is likely to report quarterly earnings at $1.90 per share on revenue of $3.71 billion. • Asbury Automotive Group (NYSE: ABG ) is likely to report quarterly earnings at $6.05 per share on revenue of $2.48 billion. • Euroseas (NASDAQ: ESEA ) is projected to report quarterly earnings at $3.23 per share on revenue of $37.40 million. • LGI Homes (NASDAQ: LGIH ) is estimated to report quarterly earnings at $4.20 per share on revenue of $758.08 million. • TC Energy (NYSE: TRP ) is expected to report quarterly earnings at $0.83 per share on revenue of $2.80 billion. • Palatin Technologies (AMEX: PTN ) is expected to report quarterly loss at $0.03 per share on revenue of $240.00 thousand. • Kornit Digital (NASDAQ: KRNT ) is estimated to report quarterly earnings at $0.24 per share on revenue of $89.77 million.

Analysts are upbeat toward S&P 500 stocks for 2022, though some of the optimism has moderated following a volatile start to the year. Between talk of higher interest rates on the way to the wind-down

Wall Street has stars in its eyes over certain stocks. That isn't a guarantee of great performance, but three of five of the Street's favorites in 2021 beat the market over the past year.

On CNBC’s “ Halftime Report Final Trades ,” Shannon Saccocia of Boston Private said Iqvia Holdings Inc (NYSE: IQV ) works with “life sciences companies to help deliver positive end points in trials through data and process enhancement.” Bryn Talkington of Requisite Capital Management named Nvidia … Full story available on Benzinga.com

IQVIA Holdings' (IQV) fourth-quarter 2021 earnings and revenues are likely to have increased year over year.

The "Halftime Report" traders give their top picks to watch for the second half.

The "Physical, Engineering, And Life Sciences Global Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global physical, engineering, and life sciences market is expected to grow from $391.44 billion in 2021 to $443.17 billion in 2022 at a compound annual growth rate (CAGR) of 13.2%. The market is expected to reach $687.28 billion in 2026 at a CAGR of 11.6%. Major players in the physical, engineering and life sciences market are IQVIA Holdings Inc, Battelle Memorial Institute, Syneos Health Inc, PRA Health Sciences Inc, Charles River Laboratories International Inc, PAREXEL International Corporation, Pharmaceutical Product Development LLC, Medpace Holdings Inc, Albany Molecular Research Inc and Hitachi High Technologies America Inc. Physical, Engineering, and Life Sciences establishments are engaged in conducting research and experimental development in physical, engineering, and life sciences such as agriculture, environmental, botany, electronics, chemistry, fisheries, forests, mathematics, veterinary and other allied subjects.

IQVIA Holdings found using ticker (IQV) now have 18 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 350 and 261 with a mean TP of 304.28. Now with the previous closing price of 247.37 this would indicate that there is a potential upside of 23.0%. The 50 day moving average now sits at 259.57 while the 200 day moving average is 250.93. The market cap for the company is $48,824m. Visit the company website at: https://www.iqvia.com [stock_market_widget type="chart" symbol="IQV" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $60,057m based on the market concensus. IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2021 financial results before the market opens on Tuesday, F

Consecutive better-than-expected top- and bottom-line performances and shareholder-friendly moves have been aiding IQVIA Holdings (IQV) stock.

IQVIA Holdings Inc (IQV) shares closed today at 0.5% below its 52 week high of $283.57, giving the company a market cap of $53B. The stock is currently up 56.6% year-to-date, up 60.1% over the past 12 months, and up 269.4% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 52.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -482.3% The company's stock price performance over the past 12 months beats the peer average by -470.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 1145.9% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Jared Holz, Oppenheimer healthcare strategist, joins 'Power Lunch' to discuss the healthcare sector and why biotech companies could struggle the most in the space. For access to live and exclusive vid